Related Experiment Video

Updated: Aug 9, 2026

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Sunitinib malate for the treatment of solid tumours: a review of current clinical data

Robert J Motzer1, Sakina Hoosen, Carlo L Bello

  • 1Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA. motzerr@mskcc.org

Expert Opinion on Investigational Drugs
|April 26, 2006
PubMed

Insights

Sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, shows promise in treating advanced renal cell carcinoma and gastrointestinal stromal tumors. This review summarizes emerging clinical data for this novel anticancer agent.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Receptor tyrosine kinases (RTKs) are crucial for cellular growth; their mutation or overexpression is linked to human cancers.
  • Sunitinib malate is an FDA-approved oral multitargeted tyrosine kinase inhibitor with antitumour and antiangiogenic properties.

Purpose of the Study:

  • To provide an updated summary of clinical experience with sunitinib malate.
  • To highlight its efficacy in treating advanced renal cell carcinoma and gastrointestinal stromal tumors.

Main Methods:

  • Review of emerging clinical data and experience with sunitinib malate.
  • Analysis of its efficacy in patients with advanced solid tumors.

Main Results:

  • Sunitinib malate is approved for advanced renal cell carcinoma and gastrointestinal stromal tumors post-imatinib therapy.
  • Demonstrated promising clinical activity in other advanced solid tumors.

Conclusions:

  • Sunitinib malate is a significant new anticancer agent with demonstrated clinical activity.
  • Further clinical experience supports its role in treating various advanced solid tumors.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...